Phaseline

Companies › Lantu Biopharma

Lantu Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Hematology, Neurology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vebeglogene autotemcel
Autologous HSPCs transduced with lentiviral vector encoding functional HBB gene
–Phase 1Beta-ThalassemiaAug 2027
vesemnogene lantuparvovec
AAV-mediated SMN1 gene delivery
SMN1Phase 1Spinal Muscular AtrophyOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06308159Vebeglogene autotemcelPhase 1Beta-ThalassemiaHematologyAug 2027
NCT06288230vesemnogene lantuparvovecPhase 1Spinal Muscular AtrophyNeurologyOct 2027

Targets

SMN1 (1)

Companies with the same targets

Novartis Gemma Biotherapeutics GeneCradle Lanyue Biotech (Hangzhou) Biocad

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.